Where comfort and clarity converge. Sequel democratizes premium everyday lenses through VSP®

Newton announces Sequel’s inclusion in VSP’s managed vision care plan, making breakthrough Convergence Boost™ technology accessible to millions of patients experiencing screen-centric lifestyles and digital eye strain
With digital eye strain affecting up to 75% of device users¹, Sequel differentiates itself with Convergence Boost technology, delivering unrivaled visual comfort and clarity for today’s visual demands
91% of Sequel wearers reported a reduction in issues commonly associated with digital eye strain with 4 out of 5 wearers highly recommending the lens^²
Sequel empowers optometric practices in the VSP network with a powerful differentiator that’s effortless to dispense and delivers impactful results for patients experiencing visual fatigue

DALLAS, Sept. 17, 2025 /PRNewswire/ — Newton, a leader in innovative eye care solutions, proudly announces Sequel’s inclusion in VSP’s managed vision care plan, making breakthrough Convergence Boost technology accessible to millions of patients experiencing screen-centric lifestyles and digital device fatigue. VSP inclusion brings digital eye strain relief to everyone, transforming it from a premium option to an accessible everyday solution.

Sequel addresses the epidemic of digital eye strain affecting up to 75% of device users with its revolutionary Convergence Boost technology. Designed for today’s visual demands, Sequel is the only lens proven to cut digital eye strain symptoms in half³, redefining everyday lenses by delivering unparalleled vision both on screen and off. The Sequel portfolio consists of Sequel 0, 38, 67 and PAL designs bringing Convergence Boost technology to all patients struggling with digital eye strain.

Sequel represents Newton’s bold expansion into comprehensive vision care solutions. Building upon over a decade of success, this portfolio expansion introduces an everyday lens that’s different from the rest. While Sequel expands the Company’s lens portfolio, Neurolenses with Contoured Prism technology remain a premium, proven, therapeutic cash pay solution.

“Sequel is the lens patients didn’t know they needed—but won’t want to go without,” said Davis Corley, CEO of Newton. “With VSP inclusion, we’re democratizing access to patented technology that works for the way we live now. VSP availability removes barriers and puts life-changing vision solutions within reach of millions.”

Sequel empowers optometric practices in the VSP network with a powerful differentiator that’s effortless to dispense and delivers impactful results for patients experiencing visual fatigue. True to Newton’s identity as a visionary health tech partner, this VSP collaboration embodies the brand’s core promise of life-enhancing innovation that prioritizes both patient well-being and provider growth.

Dr. Paul Lovero, an optometrist with experience fitting Sequel, adds his perspective: “With Sequel, my patients report their eyes feel like they are on vacation – relaxed, comfortable, and free from the usual strain, and the ease of fitting makes it a seamless addition to my practice. It’s exactly what today’s patients need.“

Through VSP inclusion, Newton expands access to Sequel’s patented technology, ensuring that advanced digital eye strain solutions are no longer limited to those who can afford premium out-of-pocket options.

To learn more about Sequel and how VSP availability enhances its potential for your practice, visit www.sequellens.com.

About Newton

Newton is an innovation company redefining eye care through exceptional patient experiences and outcomes. With patented Contoured Prism technology exclusive to the Neurolens portfolio, and breakthrough Sequel Lenses with Convergence Boost technology available soon under VSP, Newton empowers eye care providers to bring real relief to patients while elevating the standard of care across the industry.

For more information, visit www.newton.tech

¹ CooperVision (February 2024). “A New Look at Digital Eye Strain”. Report of online survey results (2023): N=750, Vision corrected patients. US Adults Ages 18-44 who wear corrective spectacles and/or contact lenses.

² Based on Consumer Product Testing of Sequel 38 and Sequel 67 designs with users experiencing existing digital eye strain symptoms, n=29 (Sequel 38), n=27 (Sequel 67)
³ Neurolens Data on File: Intelliboost CPT Study 2025 – CVS-Q